News
Important Only
The Oncology Institute Reaffirms 2025 Guidance And Provides Preliminary 2026 Outlook
Jan 12 (Reuters) - Oncology Institute Inc TOI.O:THE ONCOLOGY INSTITUTE REAFFIRMS 2025 GUIDANCE AND PROVIDES PRELIMINARY 2026 OUTLOOKONCOLOGY INSTITUTE INC - ANTICIPATES 2026 REVENUE BETWEEN $630 MILLION AND $650 MILLIONONCOLOGY INSTITUTE INC: LOOKING BEYOND 2026, CO IS WELL POSITIONED FOR CONTINUED ...Reuters
Mon, Jan 12
Cvrx Reports Preliminary Fourth Quarter And Fiscal Year 2025 Financial Results And Issues Fiscal 2026 Guidance
Jan 12 (Reuters) - CVRx Inc CVRX.O:CVRX REPORTS PRELIMINARY FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS AND ISSUES FISCAL 2026 GUIDANCECVRX INC - FY 2025 REVENUE EXPECTED TO BE $56.5 MILLION-$56.7 MILLIONCVRX INC - FY 2026 REVENUE EXPECTED TO BE $63 MILLION-$67 MILLIONReuters
Mon, Jan 12
Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
Jan 12 (Reuters) - MaxCyte Inc MXCT.O:MAXCYTE ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTSQ4 CORE REVENUE EXPECTED BETWEEN $6.6 MILLION AND $6.7 MILLIONQ4 REVENUE VIEW $9.4 MILLION -- LSEG IBES DATAFurther company coverage: MXCT.OReuters
Mon, Jan 12
Billiontoone Provides Guidance For 2026
Jan 12 (Reuters) - BillionToOne Inc BLLN.O:BILLIONTOONE PROVIDES GUIDANCE FOR 20262026 REVENUE GUIDANCE OF $415 MILLION TO $430 MILLIONREITERATES 2025 GUIDANCE OF $293 MILLION TO $299 MILLIONFY2025 REVENUE VIEW $296.2 MILLION -- LSEG IBES DATAFY2026 REVENUE VIEW $402.4 MILLION -- LSEG IBES DATAFurth...Reuters
Mon, Jan 12
Transmedics Announces New Global Headquarters And Expansion At Assembly Innovation Park In Somerville, Massachusetts
Jan 12 (Reuters) - Transmedics Group Inc TMDX.O:TRANSMEDICS ANNOUNCES NEW GLOBAL HEADQUARTERS AND EXPANSION AT ASSEMBLY INNOVATION PARK IN SOMERVILLE, MASSACHUSETTSTRANSMEDICS GROUP INC - PLANS TO RELOCATE BY JANUARY 2028Reuters
Mon, Jan 12
Progyny Inc Anticipates Q4 And Full Year Results To Be Slightly Above Previously Provided Financial Guidance
Jan 12 (Reuters) - Progyny Inc PGNY.O:PROGYNY INC: ANTICIPATES Q4 AND FULL YEAR RESULTS TO BE SLIGHTLY ABOVE PREVIOUSLY PROVIDED FINANCIAL GUIDANCESource text: [ID:n0001551306-26-000009]Reuters
Mon, Jan 12
Carlsmed's preliminary Q4 revenue rises 61% to $15.2 mln
OverviewMedical tech firm's preliminary Q4 2025 revenue grew 61% yr/yr to $15.2 mlnPreliminary full-year 2025 revenue rose 86% to $50.5 mlnCompany added 101 new surgeon users in 2025, a 61% increaseOutlookCarlsmed anticipates growing recognition and adoption of aprevo in 2026Company focuses on o...Reuters
Mon, Jan 12
Harmony Biosciences Guides To Over $1 Billion In Wakix® Revenue In 2026 Advancing Robust Late-Stage Pipeline With Potential For Long-Term Value Creation
Jan 12 (Reuters) - Harmony Biosciences Holdings Inc HRMY.O:HARMONY BIOSCIENCES GUIDES TO OVER $1 BILLION IN WAKIX® REVENUE IN 2026; ADVANCING ROBUST LATE-STAGE PIPELINE WITH POTENTIAL FOR LONG-TERM VALUE CREATIONHARMONY BIOSCIENCES Q4 PRELIM UNAUDITED NET PRODUCT REVENUE $243 MILLIONHARMONY BIOSCIEN...Reuters
Mon, Jan 12
Steakhouse operator One Group Hospitality's prelim FY25 revenue misses estimates
OverviewRestaurant operator's preliminary 2025 revenue rose 20% but missed analyst expectationsQ4 revenue fell 6.8% due to restaurant closures and fiscal changesOutlookCompany plans asset-light expansion with Benihana locations in San Francisco Bay AreaCompany aims to reduce discretionary capita...Reuters
Mon, Jan 12
Vaximm, An Osr Company, Receives Binding Term Sheet From Bcm Europe For Global Exclusive License Of Vxm01 With $30M Upfront And Up To $815M In Milestones
Jan 12 (Reuters) - OSR Holdings Inc OSRH.O:VAXIMM, AN OSR COMPANY, RECEIVES BINDING TERM SHEET FROM BCM EUROPE FOR GLOBAL EXCLUSIVE LICENSE OF VXM01 WITH $30M UPFRONT AND UP TO $815M IN MILESTONESReuters
Mon, Jan 12
Pierre Fabre Pharmaceuticals On Jan 9, Got Complete Response Letter For Tabelecleucel BLA From U.S. FDA
Jan 12 (Reuters) - Atara Biotherapeutics Inc ATRA.O:PIERRE FABRE PHARMACEUTICALS: ON JAN 9, GOT COMPLETE RESPONSE LETTER FOR TABELECLEUCEL BLA FROM U.S. FDAPIERRE FABRE: IN NEW CRL, FDA SAID IT NO LONGER CONSIDERS PREVIOUSLY ACCEPTED SINGLE-ARM ALLELE STUDY TO BE ENOUGH TO SUPPORT ACCELERATED APPROV...Reuters
Mon, Jan 12
Citi raises Cummins' PT on strong 2026 growth optimism
Citi raises PT on U.S. truck engine maker Cummins CMI.N PT to $630 from $580, on the back of strong earnings growth expectations for co in 2026 and 2027New PT represents 14.1% upside on stock's last close"We see a path to double-digit percentage earnings growth in 2026 and 2027, underpinned ...Reuters
Mon, Jan 12
Cvrx Inc - On Jan 9, Amends Existing Loan And Security Agreement Dated Oct 31 2022 - SEC Filing
Jan 12 (Reuters) - CVRx Inc CVRX.O:CVRX INC - ON JAN 9, AMENDS EXISTING LOAN AND SECURITY AGREEMENT DATED OCT 31 2022 - SEC FILINGCVRX INC - TERM LOANS INCREASED BY $50 MILLION TO $100 MILLION - SEC FILINGReuters
Mon, Jan 12
Recludix Pharma Announces Equity Financing To Advance Clinical Development Of Novel Sh2 Domain Inhibitors
Jan 12 (Reuters) - Eli Lilly and Co LLY.N:RECLUDIX PHARMA : ANNOUNCES EQUITY FINANCING TO ADVANCE CLINICAL DEVELOPMENT OF NOVEL SH2 DOMAIN INHIBITORSRECLUDIX PHARMA : FINANCING LED BY INSTITUTIONAL INVESTORS, WITH PARTICIPATION FROM NEW INVESTOR ELI LILLY AND COMPANYRECLUDIX PHARMA : TOTAL OF $123 ...Reuters
Mon, Jan 12
Morning News Call - Canada, January 12
To access a PDF version of this newsletter, please click hereYou can read Morning News Call Canada via TOPNEWS Canada page.If you would like to receive this newsletter through your email, please register at:https://solutions.lseg.com/MorningNewsCallEN-subscription-pageEX-DIVIDENDSOrla Mining Ltd: Am...Reuters
Mon, Jan 12
Vir Biotechnology Provides Updates On Chronic Hepatitis Delta And Oncology Programs And Upcoming 2026 Clinical Milestones
Jan 12 (Reuters) - Vir Biotechnology Inc VIR.O:VIR BIOTECHNOLOGY PROVIDES UPDATES ON CHRONIC HEPATITIS DELTA AND ONCOLOGY PROGRAMS AND UPCOMING 2026 CLINICAL MILESTONESVIR BIOTECHNOLOGY INC: POSITIVE, UPDATED PHASE 2 SOLSTICE DATA SHOWED COMBINATION OF TOBEVIBART AND ELEBSIRAN IS WELL TOLERATEDReuters
Mon, Jan 12
Praxis Precision Medicines Inc - Two NDA Submissions Expected By Mid-Feb 2026 For Ulixacaltamide In Essential Tremor & Relutrigine In Scn2a/8A-Dees
Jan 12 (Reuters) - Praxis Precision Medicines Inc PRAX.O:PRAXIS PRECISION MEDICINES INC - TWO NDA SUBMISSIONS EXPECTED BY MID-FEB 2026 FOR ULIXACALTAMIDE IN ESSENTIAL TREMOR & RELUTRIGINE IN SCN2A/8A-DEESReuters
Mon, Jan 12
